• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Cerus Corporation

    8/5/25 5:24:02 PM ET
    $CERS
    EDP Services
    Technology
    Get the next $CERS alert in real time by email
    S-8 1 d84103ds8.htm S-8 S-8

    As filed with the Securities and Exchange Commission on August 5, 2025

    Registration No. 333-

     

     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    CERUS CORPORATION

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   68-0262011

    (State or other jurisdiction of

    Incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

    1220 Concord Avenue, Suite 600

    Concord, California 94520

    (Address, including zip code, of principal executive offices)

    Cerus Corporation Amended and Restated 2024 Equity Incentive

    Plan

    (Full title of the plan)

    Chrystal N. Jensen

    Chief Legal Officer, General Counsel and Secretary

    Cerus Corporation

    1220 Concord Avenue, Suite 600

    Concord, California 94520

    (925) 288-6000

    (Name, address, and telephone number, including area code, of agent for service)

     

     

    Copies to:

    Chadwick L. Mills

    Cooley LLP

    3 Embarcadero Center, 20th Floor

    San Francisco, California 94111-5800

    (415) 693-2000

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☐    Accelerated filer   ☒
    Non-accelerated filer   ☐    Smaller reporting company   ☐
         Emerging growth company   ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     
     


    EXPLANATORY NOTE

    This registration statement on Form S-8 (the “Registration Statement”) is being filed for the purpose of registering an additional 10,000,000 shares of the Registrant’s Common Stock, $0.001 par value, to be issued pursuant to the Registrant’s Amended and Restated 2024 Equity Incentive Plan (the “EIP”). The shares of the Registrant’s Common Stock previously reserved for issuance under the EIP were registered on the Registrant’s Registration Statement on Form S-8 (File No. 333-281197) filed with the Securities and Exchange Commission (the “Commission”) on August  1, 2024.


    PART I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

    The documents containing the information specified in this Part I will be sent or given to participants as specified by Rule 428(b)(1) under the Securities Act of 1933, as amended (the “Securities Act”). In accordance with the rules and regulations of the Securities and Exchange Commission (the “Commission” or “SEC”) and the instructions to Form S-8, such documents are not being filed with the Commission either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 under the Securities Act.

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 3. Incorporation of Documents by Reference.

    The following documents have been filed by the Registrant with the Commission and are incorporated herein by reference:

     

      •  

    the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Commission on February 26, 2025 (the “2024 Form 10-K”);

     

      •  

    the information specifically incorporated by reference into the 2024 Form 10-K from the Registrant’s definitive proxy statement on Schedule 14A, filed with the Commission on April 23, 2025;

     

      •  

    the Registrant’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025, filed with the Commission on May 1, 2025;

     

      •  

    the Registrant’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2025, filed with the Commission on August 5, 2025;

     

      •  

    the Registrant’s Current Reports on Form 8-K, filed with the Commission on February  6, 2025, June  9, 2025 and June 23, 2025; and

     

      •  

    the description of the Registrant’s Common Stock contained in Exhibit 4.2 to the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023.

    All documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), other than current reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items, prior to the filing of a post-effective amendment to this Registration Statement which indicates that all of the shares of Common Stock offered have been sold or which deregisters all of such shares then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of the filing of such documents.

    For purposes of this Registration Statement, any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

    Item 4. Description of Securities.

    Not applicable.

    Item 5. Interests of Named Experts and Counsel.

    Not applicable.


    Item 6. Indemnification of Directors and Officers.

    As permitted by Delaware law, the Registrant’s amended and restated certificate of incorporation provides that no director will be personally liable to the Registrant or the Registrant’s stockholders for monetary damages for breach of fiduciary duty as a director, except for liability:

     

      •  

    for any breach of the duty of loyalty to the Registrant or the Registrant’s stockholders;

     

      •  

    for acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law;

     

      •  

    for unlawful payment of dividends or unlawful stock repurchases or redemptions under Section 174 of the Delaware General Corporation Law; and

     

      •  

    for any transaction from which the director derived an improper personal benefit.

    The Registrant’s amended and restated bylaws provide that:

     

      •  

    the Registrant is required to indemnify the Registrant’s directors and executive officers to the fullest extent not prohibited by law, subject to limited exceptions;

     

      •  

    the Registrant may indemnify the Registrant’s other officers, employees and agents as set forth in the Delaware General Corporation Law;

     

      •  

    the Registrant is required, to the fullest extent not prohibited by law, to advance expenses to the Registrant’s directors and executive officers as incurred in connection with legal proceedings against them for which they may be indemnified, against an undertaking by the indemnified party to repay such advances if it is ultimately determined that the indemnified party is not entitled to indemnification; and

     

      •  

    the rights conferred in the amended and restated bylaws are not exclusive.

    The Company has entered into indemnification agreements with each of the Registrant’s directors and executive officers that require the Registrant to indemnify these individuals against expenses, witness fees, damages, judgments, fines and settlement amounts incurred by the director or officer in any action or proceeding, whether actual, pending or threatened, subject to certain limitations, to which any of these individuals may be made a party by reason of the fact that he or she is or was a director or an executive officer of the Registrant or is or was serving or at any time serves at the request of the Registrant as a director, officer, employee or other agent of another corporation, partnership, joint venture, trust, employee benefit plan or other enterprise.

    Item 7. Exemption from Registration Claimed.

    Not Applicable.

    Item 8. Exhibits.

     

    Exhibit
    Number

        
     4.1(1)    Amended and Restated Certificate of Incorporation of Cerus Corporation.
     4.2(1)    Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Cerus Corporation.
     4.3(4)    Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Cerus Corporation.
     4.4(5)    Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Cerus Corporation.
     4.5(2)    Amended and Restated Bylaws of Cerus Corporation.
     4.6(3)    Specimen Stock Certificate.
     5.1    Opinion of Cooley LLP.
    23.1    Consent of Independent Registered Public Accounting Firm.
    23.2    Consent of Cooley LLP is contained in Exhibit 5.1 to this Registration Statement.
    24.1    Power of Attorney is contained on the signature pages.
    99.1(6)    Cerus Corporation Amended and Restated 2024 Equity Incentive Plan.
    107    Filing Fee Table.

     

    (1)

    Incorporated by reference to the like-described exhibit to the Registrant’s Quarterly Report on Form 10-Q (File No. 000-21937), for the quarter ended September 30, 2012, filed with the Commission on November 8, 2012.

    (2)

    Incorporated by reference to the like-described exhibit to the Registrant’s Current Report on Form 8-K (File No. 000-21937), filed with the Commission on January 5, 2024.

    (3)

    Incorporated by reference to the like-described exhibit to the Registrant’s Quarterly Report on Form 10-Q (File No. 000-21937), for the quarter ended September 30, 2009, filed with the Commission on November 6, 2009.

    (4)

    Incorporated by reference to the like-described exhibit to the Registrant’s Quarterly Report on Form 10-Q (File No. 000-21937), for the quarter ended June 30, 2014, filed with the Commission on August 8, 2014.

    (5)

    Incorporated by reference to the like-described exhibit to the Registrant’s Quarterly Report on Form 10-Q (File No. 000-21937), for the quarter ended June 30, 2021, filed with the Commission on August 3, 2021.

    (6)

    Incorporated by reference to the like-described exhibit to the Registrant’s Quarterly Report on Form 10-Q (File No. 000-21937), for the quarter ended June 30, 2025, filed with the Commission on August 5, 2025.


    Item 9. Undertakings.

    1. The undersigned Registrant hereby undertakes:

    (a) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

    (i) To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933, as amended;

    (ii) To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20 percent change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective Registration Statement.

    (iii) To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement;

    Provided, however, that paragraphs (a)(i) and (a)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference herein.

    (b) That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered herein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    (c) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

    2. The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered herein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    3. Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act of 1933 and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act of 1933 and will be governed by the final adjudication of such issue.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Concord, State of California, on this 5th day of August, 2025.

     

    Cerus Corporation

     

    By:  

    /s/ William M. Greenman

      William M. Greenman
      President and Chief Executive Officer

    POWER OF ATTORNEY

    Each person whose signature appears below constitutes and appoints William M. Greenman and Kevin D. Green, each acting alone, as his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any or all amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Commission, granting unto said attorney-in-fact and agent, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature

      

    Title

      

    Date

    /s/ William M. Greenman

    William M. Greenman

      

    President, Chief Executive Officer and Chair of

    the Board of Directors

    (Principal Executive Officer)

       August 5, 2025

    /s/ Kevin D. Green

       Chief Financial Officer    August 5, 2025
    Kevin D. Green    (Principal Financial and Accounting Officer)   

    /s/ Eric H. Bjerkholt

       Director    August 5, 2025
    Eric H. Bjerkholt      

    /s/ Dean Gregory

       Director    August 5, 2025
    Dean Gregory      

    /s/ Ann Lucena

       Director    August 5, 2025
    Ann Lucena      

    /s/ Timothy L. Moore

       Director    August 5, 2025
    Timothy L. Moore      

    /s/ Jami Nachtsheim

       Director    August 5, 2025
    Jami Nachtsheim      

    /s/ Hua Shan, M.D., Ph.D.

       Director    August 5, 2025
    Hua Shan, M.D., Ph.D.      

    /s/ Frank Witney, Ph.D.

       Director    August 5, 2025
    Frank Witney, Ph.D.      
    Get the next $CERS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CERS

    DatePrice TargetRatingAnalyst
    4/12/2024$5.00Buy
    Craig Hallum
    1/20/2023Buy → Neutral
    BTIG Research
    1/17/2023$3.75Overweight → Equal-Weight
    Stephens
    More analyst ratings

    $CERS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    The German National Blood Advisory Committee Issues Formal Recommendation for Improving the Safety of Platelet Transfusions

    Cerus Corporation (NASDAQ:CERS) announced today the publication of a new recommendation from the German National Blood Advisory Committee (Arbeitskreis Blut or AK Blut), which recommends proactive measures, including pathogen inactivation (PI) such as INTERCEPT®, as core measures to enhance the safety of platelet transfusions. AK Blut is an expert committee that advises the German federal authorities on the safety of blood, blood products, and cells for transfusion. "We believe today's recommendation from AK Blut affirms the critical role of pathogen inactivation in protecting patients from transfusion-transmitted bacterial infections. Enhancing patient safety is clearly a key priority of

    8/25/25 9:00:00 AM ET
    $CERS
    EDP Services
    Technology

    Cerus Corporation to Participate in the Cantor Global Healthcare Conference 2025

    Cerus Corporation (NASDAQ:CERS) announced today that company management will participate in a fireside chat at the Cantor Global Healthcare Conference 2025 on Wednesday, September 3, 2025, at 10:55 A.M. ET. A live webcast of the fireside chat will be available on the Events and Presentations section of the company's website at ir.cerus.com/events-and-presentations/events-and-webcasts/. A replay will be available for 30 days after the event. ABOUT CERUS Cerus Corporation is dedicated solely to safeguarding the world's blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies a

    8/21/25 8:30:00 AM ET
    $CERS
    EDP Services
    Technology

    Cerus Corporation Announces Second Quarter 2025 Financial Results

    Second Quarter Total Revenue of $60.1 Million; Record Product Revenue of $52.4 Million, Up 16% Year-Over-Year Raising Full-Year 2025 Product Revenue Guidance Range to $200 Million - $203 Million Conference Call Today at 4:30 pm ET Cerus Corporation (NASDAQ:CERS) announced financial results for the second quarter ended June 30, 2025, and provided a business update. "With our singular focus to advance blood safety and availability around the globe by establishing INTERCEPT as the standard of care, this quarter's commercial results are evidence of the progress we are making in multiple geographies and across our INTERCEPT product portfolio. The early launch and adoption of our next gen

    8/5/25 4:01:00 PM ET
    $CERS
    EDP Services
    Technology

    $CERS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Craig Hallum initiated coverage on Cerus with a new price target

    Craig Hallum initiated coverage of Cerus with a rating of Buy and set a new price target of $5.00

    4/12/24 8:00:30 AM ET
    $CERS
    EDP Services
    Technology

    Cerus downgraded by BTIG Research

    BTIG Research downgraded Cerus from Buy to Neutral

    1/20/23 10:02:56 AM ET
    $CERS
    EDP Services
    Technology

    Cerus downgraded by Stephens with a new price target

    Stephens downgraded Cerus from Overweight to Equal-Weight and set a new price target of $3.75

    1/17/23 7:57:35 AM ET
    $CERS
    EDP Services
    Technology

    $CERS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Gregory Dean A. bought $31,250 worth of shares (25,000 units at $1.25), increasing direct ownership by 41% to 86,725 units (SEC Form 4)

    4 - CERUS CORP (0001020214) (Issuer)

    8/25/25 3:25:00 PM ET
    $CERS
    EDP Services
    Technology

    Director Witney Frank was granted 60,000 shares, increasing direct ownership by 27% to 280,059 units (SEC Form 4)

    4 - CERUS CORP (0001020214) (Issuer)

    6/4/25 6:53:35 PM ET
    $CERS
    EDP Services
    Technology

    Director Moore Timothy L. was granted 60,000 shares, increasing direct ownership by 41% to 205,073 units (SEC Form 4)

    4 - CERUS CORP (0001020214) (Issuer)

    6/4/25 6:48:52 PM ET
    $CERS
    EDP Services
    Technology

    $CERS
    SEC Filings

    View All

    SEC Form S-8 filed by Cerus Corporation

    S-8 - CERUS CORP (0001020214) (Filer)

    8/5/25 5:24:02 PM ET
    $CERS
    EDP Services
    Technology

    SEC Form 10-Q filed by Cerus Corporation

    10-Q - CERUS CORP (0001020214) (Filer)

    8/5/25 4:52:49 PM ET
    $CERS
    EDP Services
    Technology

    Cerus Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - CERUS CORP (0001020214) (Filer)

    8/5/25 4:02:33 PM ET
    $CERS
    EDP Services
    Technology

    $CERS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Gregory Dean A. bought $31,250 worth of shares (25,000 units at $1.25), increasing direct ownership by 41% to 86,725 units (SEC Form 4)

    4 - CERUS CORP (0001020214) (Issuer)

    8/25/25 3:25:00 PM ET
    $CERS
    EDP Services
    Technology

    Director Gregory Dean A. bought $2,932 worth of shares (1,725 units at $1.70), increasing direct ownership by 3% to 61,725 units (SEC Form 4)

    4 - CERUS CORP (0001020214) (Issuer)

    1/2/25 5:46:11 PM ET
    $CERS
    EDP Services
    Technology

    Shan Hua bought $4,975 worth of shares (2,500 units at $1.99), increasing direct ownership by 8% to 32,386 units (SEC Form 4)

    4 - CERUS CORP (0001020214) (Issuer)

    5/14/24 6:30:46 PM ET
    $CERS
    EDP Services
    Technology

    $CERS
    Leadership Updates

    Live Leadership Updates

    View All

    Cerus Corporation Announces Appointment of Dean Gregory to Board of Directors

    Cerus Corporation (NASDAQ:CERS) today announced the appointment of Dean Gregory to its Board of Directors. Mr. Gregory has a 30+-year career as a leader in the global blood transfusion and cell therapy industry, with broad experience across commercialization, product development, supply chain and manufacturing. For the last decade, Mr. Gregory served as President, Global Commercial Operations, Med Tech for Fresenius Kabi, the role from which he retired earlier this year. "We are very pleased to welcome Mr. Gregory to Cerus' Board of Directors," said Daniel Swisher, Chair of the Board. "Mr. Gregory brings a wealth of experience and expertise across the global transfusion medicine market, h

    7/2/24 4:00:00 PM ET
    $CERS
    EDP Services
    Technology

    Cerus Corporation Announces the Appointment of Alicia Goodman as New Chief Human Resources Officer

    Cerus Corporation (NASDAQ:CERS) announced today that Alicia Goodman has been appointed to the role of Chief Human Resources Officer (CHRO). In this role, she will focus on sustaining and evolving the talent and organizational structure to support the future of the business as the leader in safeguarding the global blood supply. Ms. Goodman will also serve as a member of the Company's Executive Leadership Team. "We are excited to welcome Alicia to the Cerus team," said William "Obi" Greenman, Cerus' president and chief executive officer. "As we advance on key global commercial and pipeline initiatives, our talent, leadership and organization structure across all levels of the organization w

    9/27/23 8:30:00 AM ET
    $CERS
    EDP Services
    Technology

    Cerus Corporation Announces Appointment of Hua Shan, MD, PhD to Board of Directors

    Cerus Corporation (NASDAQ:CERS) today announced the appointment of Hua Shan, MD, PhD, Professor of Pathology and Medical Director, Transfusion Medicine Service at Stanford Medical Center to its Board of Directors. "We are pleased to welcome Dr. Shan to Cerus' Board of Directors," said Daniel Swisher, Chair of the Board. "Dr. Shan is an accomplished, leading voice in the transfusion community, with more than twenty-five years of experience in the field, bringing a wealth of knowledge and insight to our Board. In addition, Dr. Shan has extensive experience with international blood bank practices including the Chinese transfusion market. We expect to benefit from Dr. Shan's expertise as we co

    7/5/22 5:00:00 PM ET
    $CERS
    EDP Services
    Technology

    $CERS
    Financials

    Live finance-specific insights

    View All

    Cerus Corporation Announces Second Quarter 2025 Financial Results

    Second Quarter Total Revenue of $60.1 Million; Record Product Revenue of $52.4 Million, Up 16% Year-Over-Year Raising Full-Year 2025 Product Revenue Guidance Range to $200 Million - $203 Million Conference Call Today at 4:30 pm ET Cerus Corporation (NASDAQ:CERS) announced financial results for the second quarter ended June 30, 2025, and provided a business update. "With our singular focus to advance blood safety and availability around the globe by establishing INTERCEPT as the standard of care, this quarter's commercial results are evidence of the progress we are making in multiple geographies and across our INTERCEPT product portfolio. The early launch and adoption of our next gen

    8/5/25 4:01:00 PM ET
    $CERS
    EDP Services
    Technology

    Cerus Corporation to Release Second Quarter 2025 Financial Results on August 5, 2025

    Cerus Corporation (NASDAQ:CERS) announced today that its second quarter 2025 financial results will be released on Tuesday, August 5, 2025, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET, during which management will discuss the Company's financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides, please visit the Investor Relations page of the Cerus website at http://ir.cerus.com. Participants may register for the call here. While not required, interested participants are encouraged to join 10 minutes prior to the start of the event. A replay will be avai

    7/22/25 4:15:00 PM ET
    $CERS
    EDP Services
    Technology

    Cerus Corporation Announces First Quarter 2025 Financial Results

    First quarter 2025 Product Revenue of $43.2 Million, Up 13% Over Prior Year Reiterating Full-Year 2025 Product Revenue Guidance Range of $194 - $200 Million First Quarter 2025 Total Revenue of $48.9 Million Including Government Contract Revenue of $5.6 Million Conference Call Today at 4:30 pm ET Cerus Corporation (NASDAQ:CERS) announced today financial results for the first quarter ended March 31, 2025, and provided a business update. "We are off to a strong start in 2025, executing against our stated goals and making meaningful progress in advancing Cerus' mission to transform the safety and availability of transfused blood components," said William "Obi" Greenman, Cerus' president an

    5/1/25 4:00:00 PM ET
    $CERS
    EDP Services
    Technology

    $CERS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Cerus Corporation

    SC 13G/A - CERUS CORP (0001020214) (Subject)

    11/12/24 9:53:11 AM ET
    $CERS
    EDP Services
    Technology

    SEC Form SC 13G/A filed by Cerus Corporation (Amendment)

    SC 13G/A - CERUS CORP (0001020214) (Subject)

    2/14/24 4:21:51 PM ET
    $CERS
    EDP Services
    Technology

    SEC Form SC 13G/A filed by Cerus Corporation (Amendment)

    SC 13G/A - CERUS CORP (0001020214) (Subject)

    2/13/24 5:01:03 PM ET
    $CERS
    EDP Services
    Technology